{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T01:44:53Z","timestamp":1720662293293},"reference-count":56,"publisher":"Wiley","issue":"S6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":5417,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Cardiol"],"published-print":{"date-parts":[[2000,11]]},"DOI":"10.1002\/clc.4960231107","type":"journal-article","created":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T06:55:43Z","timestamp":1247727343000},"page":"23-28","source":"Crossref","is-referenced-by-count":16,"special_numbering":"supplement S6","title":["The Future of Antiplatelet Therapy: Optimizing Management in Patients with Acute Coronary Syndrome"],"prefix":"10.1002","volume":"23","author":[{"given":"Eric J.","family":"Topol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"10.1002\/clc.4960231107-BIB1","first-page":"111","article-title":"A new blood corpuscle","volume":"1","author":"Bizzozero","year":"1882","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.CIR.54.3.365","article-title":"Platelet aggregation in partially obstructed vessels and its elimination with aspirin","volume":"54","author":"Folts","year":"1976","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1527-3466.1993.tb00275.x","article-title":"Clopidogrel, a novel antiplatelet and antithrombotic agent","volume":"11","author":"Herbert","year":"1993","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1002\/clc.4960231107-BIB4","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/01.CIR.100.15.1667","article-title":"Ticlopidine and clopidogrel","volume":"100","author":"Quinn","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB5","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.ATV.19.8.2007","article-title":"Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel","volume":"19","author":"Geiger","year":"1999","journal-title":"Arterioscler Thromb Vase Biol"},{"key":"10.1002\/clc.4960231107-BIB6","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0735-1097(99)00442-8","article-title":"Clopidogrel versus ticlopidine after intracoronary stent placement","volume":"34","author":"Berger","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960231107-BIB7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0002-9149(99)00420-8","article-title":"Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting","volume":"84","author":"Jauhar","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1002\/clc.4960231107-BIB8","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0735-1097(99)00443-X","article-title":"Clopidogrel as adjunctive antiplatelet therapy during coronary stenting","volume":"34","author":"Mishkel","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960231107-BIB9","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0735-1097(97)00073-9","article-title":"Antiplatelet effect of ticlopidine after coronary stenting","volume":"29","author":"Neumann","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960231107-BIB10","doi-asserted-by":"crossref","first-page":"99A","DOI":"10.1016\/S0735-1097(97)84139-3","article-title":"Risk factors analysis for stent occlusion within the first month after successful coronary stent placement (abstr 1032-85)","volume":"31","author":"Sch\u00f6mig","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960231107-BIB11","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/01.CIR.99.18.2364","article-title":"Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation","volume":"99","author":"Moussa","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB13","first-page":"I","article-title":"Benefit of clopidogrel in patients with coronary disease (abstr 2608)","volume":"96","author":"Gent","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB14","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1161\/01.CIR.98.22.2461","article-title":"Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates","volume":"98","author":"Harker","year":"1998","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB15","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1053\/euhj.1998.1042","article-title":"Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis","volume":"19","author":"Makkar","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1002\/clc.4960231107-BIB16","first-page":"1","article-title":"Synergy, additivism and antagonism in immunosuppression. A critical review","volume":"28","author":"Berenbaum","year":"1977","journal-title":"Clin Exp Immunol"},{"key":"10.1002\/clc.4960231107-BIB17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1055\/s-0037-1615238","article-title":"The anti-aggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit","volume":"80","author":"Herbert","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1002\/clc.4960231107-BIB18","first-page":"66A","article-title":"Short term mortality lower with clopidogrel than ticlodpidine following coronary artery stenting (abstr 1153-116)","volume":"35","author":"L'Allier","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960231107-BIB19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"key":"10.1002\/clc.4960231107-BIB20","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/29325","article-title":"A dual thrombin receptor system for platelet activation","volume":"394","author":"Kahn","year":"1998","journal-title":"Nature"},{"key":"10.1002\/clc.4960231107-BIB21","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1073\/pnas.95.12.6642","article-title":"Cloning and characterization of human protease-activated receptor 4","volume":"95","author":"Xu","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/clc.4960231107-BIB22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI6042","article-title":"Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin","volume":"103","author":"Kahn","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1002\/clc.4960231107-BIB23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","article-title":"Platelet GPIIb-IIIa blockers","volume":"353","author":"Topol","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960231107-BIB25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"The PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960231107-BIB26","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II","volume":"349","author":"The IMPACT-II Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB27","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","author":"The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960231107-BIB28","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960231107-BIB29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB30","article-title":"A randomized trial of potent platelet IIb\/IIIa antagonism, heparin, or both in patients with unstable angina: The PARAGON study (abstr 3234)","volume":"94","author":"PARAGON Investigators","year":"1996","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB31","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study","volume":"349","author":"The CAPTURE Investigators","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB32","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","author":"The RESTORE Investigators","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB33","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(99)10018-7","article-title":"Outcomes at 1 year and economic implications of platelet glycoprotein IIb\/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial","volume":"354","author":"Topol","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0735-1097(96)00428-7","article-title":"Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures","volume":"29","author":"Gregorini","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960231107-BIB35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0002-8703(99)70104-3","article-title":"Long-term oral platelet glycoprotein IIb\/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) trial","volume":"138","author":"Newby","year":"1999","journal-title":"Am Heart J"},{"key":"10.1002\/clc.4960231107-BIB36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9149(99)00778-X","article-title":"Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy","volume":"85","author":"Holmes","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1002\/clc.4960231107-BIB37","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.CIR.97.11.1046","article-title":"Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation","volume":"97","author":"Rupprecht","year":"1998","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB38","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1182\/blood.V92.9.3240","article-title":"Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb\/IIIa (\u03b1IIbb\u03033) inhibitors","volume":"92","author":"Peter","year":"1998","journal-title":"Blood"},{"key":"10.1002\/clc.4960231107-BIB39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1018754309025","article-title":"Assessing the optimal level of platelet inhibition with GPIIb\/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study","volume":"9","author":"Steinhubl","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"10.1002\/clc.4960231107-BIB40","first-page":"44A","article-title":"A prospective multicenter study to determine the optimal level of platelet inhibition with GPIIb\/IIIa inhibitors in patients undergoing coronary intervention: The GOLD study, (abstr 1107-83)","volume":"35","author":"Steinhubl","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960231107-BIB41","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0735-1097(97)00510-X","article-title":"Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease","volume":"31","author":"Furman","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960231107-BIB42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0049-3848(99)00019-5","article-title":"Differences between activation thresholds for platelet P-selectin and glycoprotein IIb-IIIa expression and their clinical implications","volume":"95","author":"Holmes","year":"1999","journal-title":"Thromb Res"},{"key":"10.1002\/clc.4960231107-BIB43","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1161\/circ.99.18.2476\/d","article-title":"Significance of soluble P-selectin, von Willebrand factor, and other adhesion molecules in hypercholesterolemia and peripheral artery disease (letter)","volume":"99","author":"Blann","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB44","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/s-0037-1615402","article-title":"Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40","volume":"80","author":"Slupsky","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1002\/clc.4960231107-BIB45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/35393","article-title":"CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nature"},{"key":"10.1002\/clc.4960231107-BIB46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/01.CIR.100.6.614","article-title":"Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes","volume":"100","author":"Aukrust","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB47","first-page":"254A","article-title":"The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and the PFA-100\u00ae (abstr 1104-68)","volume":"33","author":"Poggio","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960231107-BIB48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0049-3848(93)90164-J","article-title":"Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients","volume":"71","author":"Grotemeyer","year":"1993","journal-title":"Thromb Res"},{"key":"10.1002\/clc.4960231107-BIB49","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)63447-2","article-title":"Platelet glycoprotein IIIa polymorphism and coronary thrombosis","volume":"350","author":"Nurden","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB50","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(97)05399-3","article-title":"Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis","volume":"350","author":"Walter","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB51","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJM199604253341703","article-title":"A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis","volume":"334","author":"Weiss","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960231107-BIB52","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/01.CIR.99.8.1005","article-title":"P1A polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement","volume":"99","author":"Kastrati","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/clc.4960231107-BIB53","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0140-6736(98)05054-5","article-title":"Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation (letter)","volume":"353","author":"Undas","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/clc.4960231107-BIB54","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/euhj.1998.1203","article-title":"Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, P1A2, Zwb) positive platelets in patients with cardiovascular disease","volume":"20","author":"Goodall","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1002\/clc.4960231107-BIB55","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960231107-BIB56","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960231107","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/clc.4960231107\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T23:54:56Z","timestamp":1625183696000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960231107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":56,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2000,11]]}},"URL":"https:\/\/doi.org\/10.1002\/clc.4960231107","relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}